HRP20141080T1 - Pharmaceutical compositions with (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and an insulin secretagogue - Google Patents

Pharmaceutical compositions with (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and an insulin secretagogue Download PDF

Info

Publication number
HRP20141080T1
HRP20141080T1 HRP20141080AT HRP20141080T HRP20141080T1 HR P20141080 T1 HRP20141080 T1 HR P20141080T1 HR P20141080A T HRP20141080A T HR P20141080AT HR P20141080 T HRP20141080 T HR P20141080T HR P20141080 T1 HRP20141080 T1 HR P20141080T1
Authority
HR
Croatia
Prior art keywords
insulin secretagogue
combination
glimepiride
glipizide
use according
Prior art date
Application number
HRP20141080AT
Other languages
Croatian (hr)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd filed Critical Taisho Pharmaceutical Co., Ltd
Publication of HRP20141080T1 publication Critical patent/HRP20141080T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Claims (12)

1. Farmaceutski pripravak naznačen time da sadrži kombinaciju (A) (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitol ili njegovu farmaceutski prihvatljivu sol, ili hidrat spoja ili njegovu sol; i (B) sekretagog inzulina.1. Pharmaceutical preparation characterized in that it contains a combination (A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or its salt; and (B) insulin secretagogue. 2. Farmaceutski pripravak prema zahtjevu 1, naznačen time da sekretagog inzulina je glipizid, glibenklamid, ili glimepirid.2. Pharmaceutical preparation according to claim 1, characterized in that the insulin secretagogue is glipizide, glibenclamide, or glimepiride. 3. Farmaceutski pripravak prema zahtjevu 2, naznačen time da sekretagog inzulina je glipizid ili glimepirid.3. Pharmaceutical preparation according to claim 2, characterized in that the insulin secretagogue is glipizide or glimepiride. 4. Farmaceutski pripravak prema zahtjevu 2, naznačen time da sekretagog inzulina je glipizid.4. Pharmaceutical preparation according to claim 2, characterized in that the insulin secretagogue is glipizide. 5. Farmaceutski pripravak prema zahtjevu 2, naznačen time da sekretagog inzulina je glimepirid.5. Pharmaceutical preparation according to claim 2, characterized in that the insulin secretagogue is glimepiride. 6. Kombinacija: (A) (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitola ili njegove farmaceutski prihvatljive soli, ili hidrata spoja ili njegove soli; i (B) ekretagoga inzulina, naznačena time da je za uporabu u postupku sprečavanja ili liječenja dijabetes melitusa, bolesti povezanih s dijabetes melitusom, ili komplikacija dijabetes melitusa, pri čemu se (A) i (B) daju pacijentu kojem je to potrebno istovremeno ili odvojeno.6. Combination: (A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol or its pharmaceutically acceptable salt, or hydrate of the compound or its salts; and (B) insulin ecretagogue, characterized in that it is for use in a method of preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus, wherein (A) and (B) are administered to a patient in need simultaneously or separately. 7. Kombinacija za uporabu prema zahtjevu 6, naznačena time da sekretagog inzulina je glipizid, glibenklamid, i glimepirid.7. Combination for use according to claim 6, characterized in that the insulin secretagogue is glipizide, glibenclamide, and glimepiride. 8. Kombinacija za uporabu prema zahtjevu 7, naznačena time da sekretagog inzulina je glipizid ili glimepirid.8. Combination for use according to claim 7, characterized in that the insulin secretagogue is glipizide or glimepiride. 9. Kombinacija za uporabu prema zahtjevu 7, naznačena time da sekretagog inzulina je glipizid.9. Combination for use according to claim 7, characterized in that the insulin secretagogue is glipizide. 10. Kombinacija za uporabu prema zahtjevu 7, naznačena time da sekretagog inzulina je glimepirid.10. Combination for use according to claim 7, characterized in that the insulin secretagogue is glimepiride. 11. Kombinacija za uporabu prema bilo kojem zahtjevu od 6 do 10, naznačena time da dijabetes melitus je dijabetes tipa 2.11. The combination for use according to any one of claims 6 to 10, characterized in that the diabetes mellitus is type 2 diabetes. 12. Kombinacija za uporabu prema bilo kojem zahtjevu od 6 do 11, naznačena time da komplikacija dijabetes melitusa je dijabetička retinopatija, dijabetička nefropatija, dijabetička neuropatija, cerebrovaskularni poremećaj, ishemijska bolest srca, ili bolest perifernih arterija.12. The combination for use according to any one of claims 6 to 11, characterized in that the complication of diabetes mellitus is diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cerebrovascular disorder, ischemic heart disease, or peripheral artery disease.
HRP20141080AT 2009-04-16 2014-11-05 Pharmaceutical compositions with (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and an insulin secretagogue HRP20141080T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16

Publications (1)

Publication Number Publication Date
HRP20141080T1 true HRP20141080T1 (en) 2015-01-02

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20131120AT HRP20131120T1 (en) 2009-04-16 2013-11-25 Pharmaceutical compositions comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
HRP20141080AT HRP20141080T1 (en) 2009-04-16 2014-11-05 Pharmaceutical compositions with (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and an insulin secretagogue

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20131120AT HRP20131120T1 (en) 2009-04-16 2013-11-25 Pharmaceutical compositions comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes

Country Status (30)

Country Link
US (1) US20120040898A1 (en)
EP (3) EP2419097B1 (en)
JP (4) JP5077786B2 (en)
KR (2) KR20150046382A (en)
CN (7) CN105434430A (en)
AR (1) AR076317A1 (en)
AU (1) AU2010237748B2 (en)
BR (1) BRPI1012539A2 (en)
CA (1) CA2755392A1 (en)
CY (2) CY1114703T1 (en)
DK (2) DK2601949T3 (en)
ES (2) ES2523408T3 (en)
HK (6) HK1217301A1 (en)
HR (2) HRP20131120T1 (en)
ME (2) ME01555B (en)
MX (1) MX2011010901A (en)
MY (3) MY156679A (en)
NZ (4) NZ595314A (en)
PH (3) PH12015500235B1 (en)
PL (2) PL2601949T3 (en)
PT (2) PT2419097E (en)
RS (2) RS53056B (en)
RU (2) RU2532330C2 (en)
SG (6) SG2014012462A (en)
SI (2) SI2601949T1 (en)
SM (1) SMT201500015B (en)
TW (3) TW201622720A (en)
UA (2) UA105216C2 (en)
WO (1) WO2010119990A1 (en)
ZA (1) ZA201106727B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
CN102574829B (en) 2009-09-30 2015-07-01 贝林格尔.英格海姆国际有限公司 Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
UY32919A (en) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Pharmaceutical composition, pharmaceutical dosage form, procedure for its preparation, methods for its treatment and its uses
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (en) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin and glimepiride combinations.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6234443B2 (en) 2012-05-17 2017-11-22 ブイティーブイ・セラピューティクス・エルエルシー Glucokinase activator composition for the treatment of diabetes
BR112015004012A2 (en) * 2012-08-30 2017-07-04 Taisho Pharmaceutical Co Ltd combinations of sglt 2 inhibitors and antihypertensive drugs
HUE041709T2 (en) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Therapeutic uses of empagliflozin
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
LT2986304T (en) 2013-04-18 2022-03-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TW201636015A (en) * 2013-07-05 2016-10-16 卡地拉保健有限公司 Synergistic compositions
ES2869463T3 (en) * 2015-02-27 2021-10-25 Asan Found Composition for the prevention or treatment of valve calcification containing a DPP-4 inhibitor
CN105963280B (en) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 A kind of voglibose oral instant membrane and preparation method thereof
EP3528800A1 (en) 2016-10-19 2019-08-28 Boehringer Ingelheim International GmbH Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
US11439689B2 (en) * 2016-11-14 2022-09-13 Kaohsiung Medical University Method for detecting whether glucose metabolism is abnormal, and prevention and treatment therefor
US20210113561A1 (en) 2018-04-17 2021-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (en) 2018-06-01 2019-12-11 김유찬 Metering induction
CN112040945A (en) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 Therapeutic use of glucokinase activators in combination with insulin or insulin analogs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (en) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmaceutical preparation containing metformin and process for its preparation
JP2003520759A (en) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド Sustained-release tablet with unit core
CN100577175C (en) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
HUP0600232A2 (en) * 2001-04-11 2006-08-28 Bristol Myers Squibb Co Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
MX2008016231A (en) * 2006-06-29 2009-01-16 Taisho Pharma Co Ltd C-phenyl 1-thioglucitol compound.
JP5194588B2 (en) * 2006-07-06 2013-05-08 大正製薬株式会社 Diabetes preventive or therapeutic agent containing 1-thio-D-glucitol derivative as an active ingredient
WO2008020011A1 (en) * 2006-08-15 2008-02-21 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
BRPI0718596B8 (en) * 2006-11-09 2021-05-25 Boehringer Ingelheim Int pharmaceutical compositions for combination therapy with sglt-2 and metformin inhibitors
RU2009126767A (en) * 2006-12-14 2011-01-20 Тайсо Фармасьютикал Ко., Лтд. (Jp) 1-Phenyl-1-thio-d-glucitol derivative
CL2008002427A1 (en) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Pharmaceutical composition comprising 1-chloro-4- (bd-glucopyranos-1-yl) -2- [4 - ((s) -tetrahydrofuran-3-yloxy) benzyl] -benzene combined with 1 - [(4-methylquinazolin- 2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -aminopiperidin-1-yl) xanthine; and its use to treat type 2 diabetes mellitus.
PE20090603A1 (en) 2007-08-16 2009-06-11 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION INCLUDING A SGLT2 INHIBITOR AND A DPP IV INHIBITOR

Also Published As

Publication number Publication date
JP2015063543A (en) 2015-04-09
JP5660094B2 (en) 2015-01-28
RU2532330C2 (en) 2014-11-10
JP5077786B2 (en) 2012-11-21
KR20150046382A (en) 2015-04-29
SG2014014807A (en) 2014-05-29
SG2014012553A (en) 2014-05-29
NZ623838A (en) 2015-09-25
HK1218871A1 (en) 2017-03-17
MY156679A (en) 2016-03-15
TW201622720A (en) 2016-07-01
AU2010237748B2 (en) 2014-10-30
SMT201500015B (en) 2015-03-05
CN105343060A (en) 2016-02-24
US20120040898A1 (en) 2012-02-16
RS53056B (en) 2014-04-30
EP2601949A3 (en) 2013-09-18
EP2829271A3 (en) 2015-05-27
JP2013006854A (en) 2013-01-10
CN105434430A (en) 2016-03-30
JP5910711B2 (en) 2016-04-27
CY1114703T1 (en) 2016-10-05
TW201103534A (en) 2011-02-01
WO2010119990A1 (en) 2010-10-21
EP2601949B1 (en) 2014-10-29
PH12015500235A1 (en) 2015-12-02
UA105216C2 (en) 2014-04-25
MY183793A (en) 2021-03-16
HK1217434A1 (en) 2017-01-13
JP2012524710A (en) 2012-10-18
TW201500043A (en) 2015-01-01
PL2419097T3 (en) 2014-02-28
HK1217435A1 (en) 2017-01-13
JP2016104775A (en) 2016-06-09
EP2419097B1 (en) 2013-09-25
AR076317A1 (en) 2011-06-01
DK2419097T3 (en) 2013-10-28
CN105477639A (en) 2016-04-13
PL2601949T3 (en) 2015-04-30
UA111742C2 (en) 2016-06-10
PH12019500961B1 (en) 2020-08-03
HRP20131120T1 (en) 2013-12-20
PH12019500961A1 (en) 2020-08-03
SG175154A1 (en) 2011-11-28
PH12019500959A1 (en) 2020-06-29
PT2601949E (en) 2014-11-12
CY1115907T1 (en) 2017-01-25
DK2601949T3 (en) 2015-01-05
CN102395364A (en) 2012-03-28
RU2014121260A (en) 2015-12-10
CN105343059A (en) 2016-02-24
ES2431300T3 (en) 2013-11-25
NZ710575A (en) 2016-06-24
CN105343880A (en) 2016-02-24
KR20120016051A (en) 2012-02-22
SI2419097T1 (en) 2014-01-31
HK1217302A1 (en) 2017-01-06
RS53761B1 (en) 2015-06-30
NZ595314A (en) 2013-03-28
HK1218881A1 (en) 2017-03-17
SI2601949T1 (en) 2014-12-31
EP2601949A2 (en) 2013-06-12
EP2829271A2 (en) 2015-01-28
PH12015500235B1 (en) 2015-12-02
SG2014012405A (en) 2014-05-29
ES2523408T3 (en) 2014-11-25
SG2014015093A (en) 2014-04-28
BRPI1012539A2 (en) 2016-03-29
MX2011010901A (en) 2011-11-01
HK1217301A1 (en) 2017-01-06
CA2755392A1 (en) 2010-10-21
CN105343871A (en) 2016-02-24
ME01555B (en) 2014-04-20
SG2014012462A (en) 2014-05-29
NZ606888A (en) 2014-07-25
JP6066144B2 (en) 2017-01-25
EP2419097A4 (en) 2012-09-05
ZA201106727B (en) 2012-11-28
ME02015B (en) 2015-05-20
PT2419097E (en) 2013-10-03
RU2011146335A (en) 2013-05-27
AU2010237748A1 (en) 2011-10-20
PH12019500959B1 (en) 2020-06-29
EP2419097A1 (en) 2012-02-22
MY182720A (en) 2021-02-03

Similar Documents

Publication Publication Date Title
HRP20141080T1 (en) Pharmaceutical compositions with (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and an insulin secretagogue
HRP20231586T1 (en) Glucagon-like peptide 1 receptor agonists
HRP20181025T1 (en) Pharmaceutical composition comprising a glp-1-agonist, an insulin, and methionine
HRP20151230T1 (en) Lixisenatide as add-on to metformin in the treatment of diabetes type 2
HRP20161620T1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP2008545715A5 (en)
HRP20151068T1 (en) Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
ES2556466T3 (en) Lixisenatide and metformin for the treatment of type 2 diabetes
BRPI0818687A2 (en) spiro compound, the pharmaceutically acceptable salt thereof or the solvate thereof, pharmaceutical composition, gpr40 agonist medicament, insulin secretion promoting agent or a hypoglycemic agent, use of the spiro compound, the pharmaceutically acceptable salt thereof or the solvate thereof, and methods for gpr40 activation, to promote insulin secretion or to lower blood glucose level, and to treat or prevent a disease.
Karau et al. Hypoglycemic activity of aqueous and ethylacetate leaf and stem bark extracts of" Pappea capensis" in alloxan-induced diabetic BALB/c mice
JP6438944B2 (en) Insulin glargine / lixisenatide fixed ratio formulation
HRP20151087T1 (en) Prevention of hypoglycaemia in diabetes mellitus type 2 patients
JP2019517542A5 (en)
HRP20120948T1 (en) Pyridine derivatives useful as glucokinase activators
RU2012123739A (en) PHARMACEUTICAL COMPOSITION CONTAINING GPP-1 AND METIONIN AGONIST
MX2011007371A (en) Method for treating hyperglycemia with glp-1.
KR101860120B1 (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
JP2017538705A5 (en)
EA201792030A1 (en) TREATMENT OF PATIENTS WITH DIABETES MELLITUS TYPE 2
JP2018509419A5 (en)
RU2018139578A (en) A method of treating hyperglycemia
JP2018503644A5 (en)
JP2012517459A5 (en)
CA2750074A1 (en) Use of cardiotrophin-1 for the treatment of metabolic diseases
JP2010526857A5 (en)